Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Alogliptin tablets (single agent) - selected U.S. labeling
Product / population
Adults with type 2 diabetes; oral alogliptin single-agent tablets, not alogliptin/metformin or alogliptin/pioglitazone combinations.
Renal method
Creatinine clearance (CrCl) in mL/min, as specified in the selected U.S. labeling.
Source revision
Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
NESINA: single-agent renal dosing is not combination eligibility
Alogliptin renal doses and HD timing do not determine eligibility for an alogliptin/metformin fixed combination. Peritoneal dialysis remains unstudied.
What to reconcile: Check every component and the dialysis modality before applying the single-agent schedule.
U.S. product labeling / DailyMed · Adults with type 2 diabetes; oral alogliptin single-agent tablets, not alogliptin/metformin or alogliptin/pioglitazone combinations.
Renal method: Creatinine clearance (CrCl) in mL/min, as specified in the selected U.S. labeling. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Check kidney function before initiation and periodically. Hemodialysis timing does not require changing administration time. Peritoneal dialysis was not studied in the label.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.